Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial

CONCLUSIONS: Luminal B-like BCs with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.PMID:34667023 | DOI:10.1158/1078-0432.CCR-21-2260
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research